Neuromyelitis Optica (NMO) Autoantibody, IgG
Order Code: NMOIGG
Epic Lab Code: LAB3699
Order Form: A-1a Miscellaneous Request or Epic Req
Commercial Mail-out Laboratory
6240 RCP
356-3527
Specimen:
Serum
Collection Medium:
Red top tube
Minimum:
2.0 mL serum in a red-top tube
Rejection Criteria:
Specimens other than serum.
Delivery Instructions:
Deliver to laboratory immediately after collection.
Analytic Time:
10 days upon receipt in reference laboratory
Reference Range:
NMO/AQP4-IgG: <1.6 U/mL
Interpretive Data:
A positive value is consistent with a neuromyelitis optica (NMO) spectrum disorder and justifies initiation of appropriate immunosuppressive therapy at the earliest possible time. Positive AQP4- IgG enzyme-linked immunosorbent assay results are > or =5 units/mL. Negative results are <1.6 units/mL. Sera yielding indeterminate results (1.6-4.9 units/mL) will be reflexed to NMO-IgG indirect immunofluorescence testing for confirmation of positivity. NMO-IgG indirect immunofluorescence is positive if an NMO-specific immunostaining pattern is detected at a dilution of > or =1:60.
Comments:
Useful For:
Establishing the diagnosis of an neuromyelitis optica spectrum disorder and distinguishing one of these disorders from multiple sclerosis early in the course of disease, allowing early initiation, and maintenance, of optimal therapy.

Cautions:
Seronegativity does not exclude the diagnosis of a neuromyelitis optica spectrum disorder (current seronegativity rate is 23%).

Seronegativity may reflect immunosuppressant therapy.
Methodology:
NMO/AQP4-IgG Enzyme-Linked Immunosorbent Assay; Indirect Immunofluorescence
CPT Code:
83520, 86255 (if appropriate)
 
See Additional Information:
Specimens Requiring Immediate Delivery